Biologics for the Treatment of Rheumatoid Arthritis by Ronald van Vollenhoven
By Ronald van Vollenhoven
This ebook presents a accomplished review of the to be had biologic remedies when evaluating them to straightforward sickness editing anti-rheumatic medicinal drugs, and discusses how top to figure out which remedy is best for somebody sufferer within the framework of present directions. Biologics for the therapy of Rheumatoid Arthritis is an updated and concise useful consultant to the newest healing advancements during this box. This booklet is a useful resource of topical details for all rheumatologists and overall healthiness care execs treating sufferers with rheumatoid arthritis.
Read or Download Biologics for the Treatment of Rheumatoid Arthritis PDF
Similar rheumatology books
If it have been a affliction, again ache will be known as a plague. a minimum of five million humans will seek advice their GPs approximately again ache this yr. the full expenditures to the united kingdom are envisioned at #12 billion/year. This booklet info the typical stipulations which reason again discomfort and descriptions a technique for the prognosis, research and therapy of the stipulations.
Get cutting-edge assurance of the total diversity of imaging strategies to be had to aid within the analysis and healing administration of rheumatic illnesses. Written through stated specialists in musculoskeletal imaging, this richly illustrated, full-color textual content provides the newest diagnostic and sickness tracking modalities - MRI, CT, ultrasonography, nuclear drugs, DXA - in addition to interventional strategies.
"Problem fixing in Rheumatology" joins this becoming sequence. Co-authored by means of Lee Kennedy who wrote "Problem fixing in Diabetes", this may be a major contribution in a big and fast-paced scientific sector. every one medical case will spotlight how contemporary advancements in medical and pharmaceutical study have had key influence at the perform of rheumatology.
Tendon Regeneration: figuring out Tissue body structure and improvement to Engineer useful Substitutes is the 1st booklet to focus on the multi-disciplinary nature of this really expert box and the significance of collaboration among scientific and engineering laboratories within the improvement of tissue-oriented items for tissue engineering and regenerative drugs (TERM) suggestions.
- Osteoporosis - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
- Osteoporosis in Older Persons: Advances in Pathophysiology and Therapeutic Approaches
- Manual of Thoracic Surgery, 2nd Edition
- Clinical Tests for the Musculoskeletal System (Flexibook)
- Elbow Ulnar Collateral Ligament Injury: A Guide to Diagnosis and Treatment
- Ulcers of the Lower Extremity
Extra resources for Biologics for the Treatment of Rheumatoid Arthritis
1996;35:231-240. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med. 1996;24:733-742. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.
However, because the latter are based on Phase III clinical trials they are often not very relevant for clinical practice, being either too general to be useful (‘approved for patients with active disease’) or too vague (‘having failed other therapies’). Thus, many professional organizations have published guidelines on the use of biologics, and these have also been revised on several occasions. Moreover, health care payers are increasingly determining the uses of medications that can be reimbursed.
1). In addition, a small-molecular agent with biologic-like effects has been approved in the US (and many other countries around world), an anti-TNF biosimilar has been approved in Europe, and additional biologics are in late-stage development for RA. 1. They differ in structure, half-life, route of administration (intravenous or subcutaneous), dose, frequency, and in some practical aspects, but they are remarkably similar in both efficacy and safety. National and international recommendations and guidance documents generally treat these medications as a single group.